ARTICLE | Clinical News
Chugai's IL-6 receptor mAb meets in Phase III for rare CNS disorder
December 21, 2018 7:26 PM UTC
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said satralizumab (SA237, RG6168) as monotherapy met the primary endpoint in the Phase III SAkuraStar trial to treat neuromyelitis optica spectrum disorder (NMOSD). The company plans to submit regulatory applications for the humanized mAb targeting IL-6 receptor, but did not disclose details.
There are no approved therapies for NMOSD, a rare complement-mediated disorder of the CNS characterized by inflammatory lesions in the optic nerves and spinal cord...
BCIQ Target Profiles